<DOC>
	<DOCNO>NCT02523391</DOCNO>
	<brief_summary>The purpose study compare pharmacokinetics capsule tablet formulation TA-8995 healthy male subject age 18 55 year .</brief_summary>
	<brief_title>Bioequivalence Study Capsule Tablet Formulations TA-8995</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Healthy male age 1855 Body Mass Index ( BMI ) 18.0 32.0 kg/m2 , inclusive Subject know hypersensitivity inactive ingredient study treatment . Subject condition , Investigator 's opinion interfere study . Subjects still participate another clinical study ( eg , attend followup visit ) participate clinical study involve administration investigational drug ( new chemical entity ) within 3 month 5 halflives ( whichever longer ) prior first dose study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>